HALO in the 13F filings
Halozyme Therapeutics Inc · CUSIP 40637H109
- Quarter end
- 30 Sep 2026
- the date the book describes
- Filed
- 9 Nov 2026
- latest of these filings; the earliest 9 Nov 2026
- Managers listing it
- 2
- at least, of 95 tracked, among listed positions
- Comparable managers
- 5
- filed both Q2 2026 and Q3 2026; 0 listed it in both
- Shares listed
- 283,814
- combined, among listed positions
- Reported value
- $31m
- combined, at the quarter end
Among the 5 comparable managers: 2 buyers (opened or added shares) and 0 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +243,457.
Managers listing HALO in Q3 2026
2 of 2 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Squarepoint Ops LLC | 278,742 | $31m | under 0.1% | Added | +241,707 | 9 Nov 2026 (the filing on sec.gov) |
| Acadian Asset Management LLC | 5,072 | $558k | under 0.1% | Added | +1,750 | 9 Nov 2026 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Squarepoint Ops LLCexisting position · 278,742 shares now+241,707
- Acadian Asset Management LLCexisting position · 5,072 shares now+1,750
Reductions
No reduction among listed positions.
New positions and exits
New (0)
No new position among listed positions.
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2013 | 1 | $19m | n.a. | n.a. |
| Q1 2014 | 1 | $18m | n.a. | n.a. |
| Q2 2014 | 1 | $28m | n.a. | n.a. |
| Q3 2014 | 1 | $33m | n.a. | n.a. |
| Q4 2014 | 3 | $46m | n.a. | n.a. |
| Q1 2015 | 2 | $123m | n.a. | n.a. |
| Q2 2015 | 2 | $218m | n.a. | n.a. |
| Q3 2015 | 2 | $96m | n.a. | n.a. |
| Q4 2015 | 2 | $75m | n.a. | n.a. |
| Q1 2016 | 1 | $63m | n.a. | n.a. |
| Q2 2016 | 1 | $61m | n.a. | n.a. |
| Q3 2016 | 2 | $90m | n.a. | n.a. |
| Q4 2016 | 3 | $77m | n.a. | n.a. |
| Q1 2017 | 3 | $110m | n.a. | n.a. |
| Q2 2017 | 3 | $109m | n.a. | n.a. |
| Q3 2017 | 3 | $150m | n.a. | n.a. |
| Q4 2017 | 5 | $169m | n.a. | n.a. |
| Q1 2018 | 7 | $159m | n.a. | n.a. |
| Q2 2018 | 4 | $87m | n.a. | n.a. |
| Q3 2018 | 4 | $105m | n.a. | n.a. |
| Q4 2018 | 5 | $86m | n.a. | n.a. |
| Q1 2019 | 6 | $86m | n.a. | n.a. |
| Q2 2019 | 7 | $98m | n.a. | n.a. |
| Q3 2019 | 5 | $79m | n.a. | n.a. |
| Q4 2019 | 8 | $177m | n.a. | n.a. |
| Q1 2020 | 9 | $378m | n.a. | n.a. |
| Q2 2020 | 8 | $619m | n.a. | n.a. |
| Q3 2020 | 8 | $540m | n.a. | n.a. |
| Q4 2020 | 9 | $752m | n.a. | n.a. |
| Q1 2021 | 7 | $712m | n.a. | n.a. |
| Q2 2021 | 7 | $769m | n.a. | n.a. |
| Q3 2021 | 7 | $648m | n.a. | n.a. |
| Q4 2021 | 8 | $635m | n.a. | n.a. |
| Q1 2022 | 7 | $611m | n.a. | n.a. |
| Q2 2022 | 10 | $634m | n.a. | n.a. |
| Q3 2022 | 8 | $537m | n.a. | n.a. |
| Q4 2022 | 9 | $886m | n.a. | n.a. |
| Q1 2023 | 6 | $339m | n.a. | n.a. |
| Q2 2023 | 6 | $394m | n.a. | n.a. |
| Q3 2023 | 3 | $527m | n.a. | n.a. |
| Q4 2023 | 6 | $407m | 4 | 2 |
| Q1 2024 | 5 | $326m | 3 | 3 |
| Q2 2024 | 5 | $384m | 2 | 4 |
| Q3 2024 | 5 | $409m | 2 | 2 |
| Q4 2024 | 8 | $335m | 5 | 3 |
| Q1 2025 | 9 | $539m | 7 | 1 |
| Q2 2025 | 10 | $422m | 6 | 4 |
| Q3 2025 | 14 | $1.1bn | 10 | 4 |
| Q4 2025 | 13 | $885m | 13 | 23 |
| Q1 2026 | 11 | $710m | 15 | 15 |
| Q2 2026 | 11 | $732m | 17 | 16 |
| Q3 2026 | 1 | $31m | 2 | 0 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
HALO and GILD →HALO and AMGN →HALO and ARGX →Choose a stock to compare with HALO →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own HALO, latest filings →Back to the 13F Explorer →